Biohaven Stock Analysis

BHVN -  USA Stock  

USD 94.99  0.72  0.76%

The latest price rise of Biohaven Pharmaceutical could raise concerns from institutional investors as the firm it trading at a share price of 94.99 on very low momentum in volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 2.95. The current volatility is consistent with the ongoing market swings in May 2021 as well as with Biohaven Pharmaceutical unsystematic, company-specific events.
Continue to Trending Equities.

Search Stock Analysis 

The Biohaven Pharmaceutical stock analysis report makes it easy to digest most publicly released information about Biohaven Pharmaceutical and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Biohaven stock analysis module also helps to analyze the Biohaven Pharmaceutical price relationship with some important fundamental indicators such as market cap and management efficiency.

Biohaven Stock Analysis Notes

About 13.0% of the company shares are held by company insiders. The company recorded a loss per share of 13.06. Biohaven Pharmaceutical had not issued any dividends in recent years. Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut. Biohaven Pharmaceutical operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 825 people. For more info on Biohaven Pharmaceutical Holding please contact Vlad Coric at 203 404 0410 or go to

Biohaven Pharmaceutical Quarterly Cost of Revenue

12.86 MillionShare

Biohaven Pharmaceutical Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Biohaven Pharmaceutical's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Biohaven Pharmaceutical Holding or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
The company reported the previous year's revenue of 63.63 M. Net Loss for the year was (766.8 M) with profit before overhead, payroll, taxes, and interest of 45.93 M.
Biohaven Pharmaceutical Holding currently holds about 355.33 M in cash with (702.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74.
Biohaven Pharmaceutical has a poor financial position based on the latest SEC disclosures
Over 91.0% of the company shares are held by institutions such as insurance companies
Latest headline from Acquisition by Mehta Kishan of 13004 shares of Biohaven Pharmaceutical subject to Rule 16b-3

Biohaven Pharmaceutical Upcoming and Recent Events

Earnings reports are used by Biohaven Pharmaceutical to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biohaven Pharmaceutical previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report9th of August 2021
Next Earnings Report8th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End7th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Biohaven Largest EPS Surprises

Earnings surprises can significantly impact Biohaven Pharmaceutical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Biohaven Pharmaceutical SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Biohaven Pharmaceutical prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Biohaven Pharmaceutical investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Biohaven Pharmaceutical specific information freely available to individual and institutional investors to make a timely investment decision.
1st of June 2021
Financial Statements and Exhibits. Regulation FD Disclosure
10th of May 2021
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Results of Operations and Financial Condition
8th of April 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
5th of April 2021
Financial Statements and Exhibits. Other Events. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
17th of March 2021
Financial Statements and Exhibits. Other Events
15th of March 2021
Financial Statements and Exhibits. Other Events
9th of March 2021
Regulation FD Disclosure
1st of March 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition

Biohaven Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Biohaven Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biohaven Pharmaceutical Holding backward and forwards among themselves. Biohaven Pharmaceutical's institutional investor refers to the entity that pools money to purchase Biohaven Pharmaceutical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Capital International InvestorsCommon Shares5.6 M381.3 M
Capital World InvestorsCommon Shares4.7 M324 M
Blackrock IncCommon Shares3.8 M258.6 M
Marshall Wace LlpCommon Shares2.8 M189.8 M
Stifel Financial CorpCommon Shares2.6 M175.3 M
Oracle Investment Management IncCommon Shares2.1 M145.1 M
Rp Management LlcCommon Shares2.1 M144.3 M
Note, although Biohaven Pharmaceutical's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Biohaven Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 6.01 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biohaven Pharmaceutical's market, we take the total number of its shares issued and multiply it by Biohaven Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Biohaven Profitablity

Biohaven Pharmaceutical's profitability indicators refer to fundamental financial ratios that showcase Biohaven Pharmaceutical's ability to generate income relative to its revenue or operating costs. If, let's say, Biohaven Pharmaceutical is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Biohaven Pharmaceutical's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Biohaven Pharmaceutical's profitability requires more research than a typical breakdown of Biohaven Pharmaceutical's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(1.26) (1.37) 
Return on Average Equity 5.94  6.41 
Return on Invested Capital(3.40) (3.67) 
Return on Sales(10.52) (11.35) 

Management Efficiency

The entity has return on total asset (ROA) of (78.23) % which means that it has lost $78.23 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (805.55) %, meaning that it created substantial loss on money invested by shareholders. Biohaven Pharmaceutical management efficiency ratios could be used to measure how well biohaven pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Equity is expected to rise to 6.41 this year, although the value of Return on Average Assets will most likely fall to (1.37) . Biohaven Pharmaceutical Tangible Asset Value is quite stable at the moment as compared to the past year. The company's current Tangible Asset Value is estimated at 699.04 Million
Last ReportedProjected for 2021
Book Value per Share(6.65) (6.82) 
Enterprise Value over EBIT(7.00) (7.55) 
Enterprise Value over EBITDA(6.92) (7.47) 
Price to Book Value(13.16) (14.20) 
Tangible Assets Book Value per Share 11.03  9.00 
Enterprise Value5.1 B4.1 B
Tangible Asset Value647.9 M699 M

Technical Drivers

As of the 19th of June, Biohaven Pharmaceutical shows the Mean Deviation of 2.38, risk adjusted performance of 0.0824, and Downside Deviation of 3.29. Biohaven Pharmaceutical technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Biohaven Pharmaceutical Holding, which can be compared to its rivals. Please confirm Biohaven Pharmaceutical coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Biohaven Pharmaceutical is priced correctly, providing market reflects its regular price of 94.99 per share. Given that Biohaven Pharmaceutical has jensen alpha of 0.3594, we suggest you to validate Biohaven Pharmaceutical Holding's prevailing market performance to make sure the company can sustain itself at a future point.

Biohaven Pharmaceutical Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Mid-point over period is an average of Biohaven Pharmaceutical highest and lowest values attained during the given period. View also all equity analysis or get more info about midpoint over period overlap studies indicator.

Biohaven Pharmaceutical Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biohaven Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biohaven Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biohaven Pharmaceutical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Declan Doogan over a month ago via Macroaxis 
Acquisition by Declan Doogan of 11996 shares of Biohaven Pharmaceutical subject to Rule 16b-3
Michael Heffernan over two months ago via Macroaxis 
Acquisition by Michael Heffernan of tradable shares of Biohaven Pharmaceutical subject to Rule 16b-3
John Childs over three months ago via Macroaxis 
Biohaven Pharmaceutical exotic insider transaction detected
John Childs over three months ago via Macroaxis 
Biohaven Pharmaceutical exotic insider transaction detected
Vlad Coric over three months ago via Macroaxis 
Biohaven Pharmaceutical exotic insider transaction detected
Stock Elyse over three months ago via Macroaxis 
Exercise or conversion by Stock Elyse of 1250 shares of Biohaven Pharmaceutical subject to Rule 16b-3
Stock Elyse over six months ago via Macroaxis 
Exercise or conversion by Stock Elyse of 3375 shares of Biohaven Pharmaceutical subject to Rule 16b-3
John Childs over six months ago via Macroaxis 
Biohaven Pharmaceutical exotic insider transaction detected
Jones William A Jr over six months ago via Macroaxis 
Exercise or conversion by Jones William A Jr of 30000 shares of Biohaven Pharmaceutical subject to Rule 16b-3
Gregory Bailey over six months ago via Macroaxis 
Sale by Gregory Bailey of 212 shares of Biohaven Pharmaceutical
Gregory Bailey over six months ago via Macroaxis 
Sale by Gregory Bailey of 4554 shares of Biohaven Pharmaceutical
Gregory Bailey over six months ago via Macroaxis 
Sale by Gregory Bailey of 6729 shares of Biohaven Pharmaceutical

Biohaven Pharmaceutical Technical and Predictive Indicators

Biohaven Pharmaceutical Forecast Models

Biohaven Pharmaceutical time-series forecasting models is one of many Biohaven Pharmaceutical's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biohaven Pharmaceutical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Biohaven Pharmaceutical Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biohaven Pharmaceutical stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biohaven shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Biohaven Pharmaceutical. By using and applying Biohaven Stock analysis, traders can create a robust methodology for identifying Biohaven entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(10.39) (11.21) 
Gross Margin 0.65  0.65 
Profit Margin(10.85) (11.71) 
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut. Biohaven Pharmaceutical operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 825 people.

Current Biohaven Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biohaven analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biohaven analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Biohaven Pharmaceutical Holding current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Biohaven analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Biohaven stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Biohaven Pharmaceutical, talking to its executives and customers, or listening to Biohaven conference calls.
Biohaven Analyst Advice Details

Biohaven Stock Analysis Indicators

Biohaven Pharmaceutical Holding stock analysis indicators help investors evaluate how Biohaven Pharmaceutical stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biohaven Pharmaceutical shares will generate the highest return on investment. By understating and applying Biohaven Pharmaceutical stock analysis, traders can identify Biohaven Pharmaceutical position entry and exit signals to maximize returns.
Quick Ratio1.72
Fifty Two Week Low57.66
Shares Short Prior Month6.49M
Average Daily Volume Last 10 Day747.46k
Average Daily Volume In Three Month626.1k
Shares Percent Shares Out8.28%
Gross Margins72.19%
Short Percent Of Float9.34%
Forward Price Earnings-11.23
Float Shares54.31M
Fifty Two Week High106.57
Enterprise Value To Ebitda-7.18
Fifty Day Average79.61
Two Hundred Day Average80.94
Enterprise Value To Revenue71.74
Continue to Trending Equities. Note that the Biohaven Pharmaceutical information on this page should be used as a complementary analysis to other Biohaven Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Biohaven Pharmaceutical Stock analysis

When running Biohaven Pharmaceutical price analysis, check to measure Biohaven Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biohaven Pharmaceutical is operating at the current time. Most of Biohaven Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biohaven Pharmaceutical's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biohaven Pharmaceutical's price. Additionally, you may evaluate how the addition of Biohaven Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Global Correlations
Find global opportunities by holding instruments from different markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
CEO Directory
Screen CEOs from public companies around the world
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine Biohaven Pharmaceutical value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.